Clinical trials: Proton Pump Inhibitor
Upper Gastrointestinal Bleed
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
Despite recommendations from clinical practice guidelines to discharge patients from the hospital on once daily proton pump inhibitors after acute management of UGIB, clinical practice is to use twice daily proton pump inhibitor…
- Trial name
- NCT02235311
- Testing
- Pantoprazole
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Missouri-Columbia
Gastroesophageal Reflux
Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of…
- Trial name
- NCT00992589
- Testing
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-erosive Gastroesophageal Reflux Disease
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind…
- Trial name
- NCT00165646
- Testing
- E3810
- Where
- 35 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Healthy Volunteers
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
The purpose of this study is to evaluate the effect of the proton pump inhibitor (PPI) esomeprazole on the single-dose PK of orally administered TAK-906.
- Trial name
- NCT03849690
- Testing
- TAK-906, Esomeprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a…
- Trial name
- NCT01397448
- Testing
- E3810, Teprenone
- Where
- 49 sites in Japan
- Volunteers
- 472 people
- Sponsor
- Eisai Co., Ltd.
GERD Gastroesophageal Reflux Disease
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the management of reflux symptoms related to gastroesophageal reflux disease (GERD).
- Trial name
- CALIBER (NCT02505945)
- Testing
- Omeprazole, LINX Reflux Management System
- Where
- 21 sites in United States
- Volunteers
- 152 people
- Sponsor
- Torax Medical Incorporated
Human Experimentation
Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)
This study will determine differences between Proton Pump Inhibitors (PPI) formulations relative to their effects on gastric acidity.
- Trial name
- NCT01005719
- Testing
- Zegerid, Prevacid®
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Bayer
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed.
- Trial name
- R+OCA (NCT03124199)
- Testing
- Rifaximin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561090
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 99 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Transplantation, Immunosuppression
Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS
The objective of this pharmacokinetic study is to examine a possible drug-drug interaction of Pantoprazole on the bioavailability mycophenolic acid.
- Conditions
- Transplantation, Immunosuppression, Drug Interaction
- Trial name
- NCT01801280
- Testing
- Mycophenolate sodium, Pantoprazole, Mycophenolate mofetil
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Klemens Budde
Healthy Volunteer
A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
This is a Phase 1, single-center, open-label, randomized, 3-period, 2-sequence crossover study of cobimetinib in healthy participants to evaluate the effect of the proton-pump inhibitor (PPI) rabeprazole on the relative…
- Trial name
- NCT01277718
- Testing
- Cobimetinib, Rabeprazole
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Aspirin Blood Level, Proton Pump Inhiditor Treatment
Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers
Aspirin is a weak acid that crosses the gastric and intestinal mucosa by passive diffusion while in its lipophilic nature.Omeprazole, a proton pump inhibitor, inhibits gastric acid secretion.
- Trial name
- NCT01061034
- Testing
- aspirin and omeprazole
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Assaf-Harofeh Medical Center
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Erosive Esophagitis
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis.
- Trial name
- NCT00693225
- Testing
- Omeprazole/sodium bicarbonate
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Yvonne Romero
Healthy Volunteers
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.
- Trial name
- NCT05497557
- Testing
- Omeprazole, Sotorasib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.
- Trial name
- NCT05319912
- Testing
- ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Proton Pump Inhibitors
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each…
- Trial name
- RaPPID (NCT03719170)
- Testing
- PPI De-prescribing Program
- Where
- 4 sites in United States
- Volunteers
- 220,306 people
- Sponsor
- VA Office of Research and Development